T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

May 2016 | 230 pages | ID: T10DC529C94EN
La Merie Publishing

Abstracts

T-Cell Redirecting Bispecific Antibodies 2016:

A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals “ as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

Download Samples Pages: T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

• Profiles of 34 companies active in the field;
• Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
• Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
• Technology selection and preferences of major pharma;
• Key characteristics of technologies with clinical stage drug candidates
• Emerging alternative bi- and trispecific formats
• Target selection and competition in drug candiates
• Competition of recombinant bispecific molecules with alternative treatment modalities
• Dosing schedules of clinical stage drug candidates based on molecular features
• Economic terms of collaboration and licensing deals;

Who will benefit from the report?

• Venture capital, private equity and investment managers;
• Financial analysts;
• CFO;
• Business development and licensing (BDL) specialists;
• Marketing managers;
• CEO, COO and managing directors;
• Corporate strategy, product and portfolio analysts and managers;
• Chief Technology Officer;
• Cell technology and manufacturing specialists;
• Clinical and preclinical development specialists.

Contents

1 INTRODUCTION

2 EXECUTIVE SUMMARY

3 COMPETITIVE LANDSCAPE ANALYSIS

3.1 Stakeholders
  3.1.1 Major biopharmaceutical companies
  3.2.2 Small & medium pharmaceutical & biotechology companies
3.2 Technologies
3.3 Pipeline
  3.3.1 Overview
  3.3.2 Targets
  3.3.3 Competition with other Treatment Modalities
  3.3.4 Administration Regimens of T-cell Redirecting Bispecific Antibodies
  3.3.5 Next Wave of T-cell and NK-Cell Redirecting Antibodies
  3.3.6 Clincial Experience with T-cell and NK-cell redirecting Bispecific Antibodies
3.4 Commercial value of targets, drugs & technologies
  3.4.1 Drug prices and sales
  3.4.2 Economic terms of collaboration and licensing agreements
  3.4.3 Acquisition price (cost) of companies
  3.4.4 Public and private financing rounds

4. COMPANY PROFILES

4.1 Major Pharma & Biotech
  4.1.1 Amgen
  4.1.2 AstraZeneca
  4.1.3 Bayer
  4.1.4 Boehringer Ingelheim
  4.1.5 Eli Lilly
  4.1.6 GlaxoSmithKline
  4.1.7 Janssen Biotech
  4.1.8 Pfizer
  4.1.9 Roche
  4.1.10 Servier
4.2 Small & Medium Pharma & Biotech
  4.2.1 Adimab
  4.2.2 Affimed Therapeutics
  4.2.3 Alligator Biosciences
  4.2.4 Ambrx
  4.2.5 CytomX
  4.2.6 Emergent BioSolutions
  4.2.7 EngMab
  4.2.8 Eureka Therapeutics
  4.2.9 GEMoaB
  4.2.10 Generon
  4.2.11 Genmab
  4.2.12 Glenmark Pharmaceuticals
  4.2.13 Immunocore
  4.2.14 MacroGenics
  4.2.15 Merus
  4.2.16 Molecular Partners
  4.2.17 Morphosys
  4.2.18 Neovii Biotech
  4.2.19 OMT Therapeutics
  4.2.20 Pieris
  4.2.21 Regeneron Pharmaceuticals
  4.2.22 Wuhan YZY Biopharma
  4.2.23 Xencor
  4.2.24 Zymeworks

5 TECHNOLOGY PROFILES

5.1 ADAPTIR
5.2 ART-Ig
5.3 Azymetric Scaffold
5.4 BEAT
5.5 Biclonics
5.6 BiTE
5.7 CrossMab
5.8 DART
5.9 Fc-DART
5.10 Dock-and-Lock (DNL)
5.11 DuoBody
5.12 FynomAbs
5.13 ImmTAC
5.14 Knobs-into-Holes
5.15 mAbXcite
5.16 Modified VelocImmune
5.17 TandAb
5.18 T-Cell Engaging Bi-specific (TCB) Probody
5.19 Triomab
5.20 UniDab
5.21 UniTARG / UniMAB
5.22 XmAb Bispecific
5.23 Y-Body Bispecific

6 DRUG & DRUG CANDIDATE PROFILES

6.1 A-337
6.2 AFM11
6.3 AFM13
6.4 AFM21
6.5 AFM22
6.6 AFM24
6.7 AMG
6.8 AMG
6.9 AMV-564
6.10 BI 836909
6.11 Bispecific anti-CD3-folate
6.12 Blincyto
6.13 CD79b-TDB
6.14 COVA420
6.15 DR5xCD3 DART
6.16 EM801
6.17 EphA2xCD3 DART
6.18 ERY974
6.19 ES414
6.20 ES425
6.21 GBR1302
6.22 GBR1342
6.23 Her2-TDB
6.24 IL13R? DART
6.25 IMCgp100
6.26 JNJ-63709178
6.27 JNJ-64052781
6.28 M-706
6.29 M-802
6.30 MCLA-117
6.31 MGD006
6.32 MGD007
6.33 MGD009
6.34 MGD014
6.35 Pasotuxizumab
6.36 PF-06671008
6.37 PRS-343
6.38 PSMA-CD3
6.39 REGN1979
6.40 Removab
6.41 RG7802
6.42 RG7828
6.43 ROR1xCD3 DART
6.44 XmAb13551
6.45 XmAb13676
6.46 XmAb14045
6.47 ZW38

7 REFERENCES

8 ATTACHMENT

  Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
  Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
  Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
  Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D